Managing Metastatic Prostate Cancer In Your Urological Oncology Practice

1. Front Matter

   Pages i-xiii

   PDF

2. Introduction

   • K. C. Balaji

   Pages 1-3

3. Pathophysiology of Castration-Resistant Prostate Cancer

   • Justin C. Penticuff, Natasha Kyprianou

   Pages 5-22

4. Androgen Receptor Signaling in Castration Resistant Prostate Cancer

   • Yu Zhao, Donald J. Tindall, Haojie Huang

   Pages 23-34

5. Non-androgen Signaling Pathways in Castration-Resistant Prostate Cancer

   • Sivanandane Sittadjody, Thilakavathy Thangasamy, Bita NickKolgh, K. C. Balaji

   Pages 35-63

6. Predictive Models in Castration Resistant Prostate Cancer

   • Tao Cui, Michael W. Kattan

   Pages 65-75

7. Docetaxel in Advanced and Castration Resistant Prostate Cancer

   • Daniel P. Petrylak, Navid Hafez

   Pages 77-92

8. Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate

   • Ben Fulton, Robert J. Jones

   Pages 93-105

9. Cancer Vaccines in Castration Resistant Prostate Cancer—An Evolution in Design

   • Susan F. Slovin

   Pages 107-124

10. Abiraterone for the Treatment of mCRPC

    • Zafeiris Zafeiriou, Niven Mehra, Johann S. de Bono

    Pages 125-155

11. Enzalutamide in Metastatic Castration Resistant Prostate Cancer

    • Jeffrey Shevach, Bridget K. Marcellino, William K. Oh, Che-Kai Tsao

    Pages 157-169

12. Radium-223 in Metastatic Castrate Resistant Prostate Cancer

    • Tu Dan, Noelle Williams, Robert B. Den

    Pages 171-185

13. Cabazitaxel for the Treatment of Prostate Cancer

    • Michael Kolinsky, Niven Mehra, Johann S. de Bono

    Pages 187-214

14. Sequencing Therapies in Metastatic Castration—Resistant Prostate Cancer

    • Michael T. Schweizer, Bruce Montgomery

    Pages 215-230

15. Bone Preservation Strategies for Men on Androgen Deprivation Therapy

    • Charles C. Peyton, K. C. Balaji

    Pages 231-257

16. Novel Therapies in Castration-Resistant Prostate Cancer

    • Tyler Lash, Rhonda L. Bitting

    Pages 259-269

17. Back Matter

    Pages 271-280

    PDF

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

• Abiraterone Acetate
• Cabazitaxel
• Docetaxol Chemotherapy
• Enzalutamide
• castration resistant prostate cancer

• School of Medicine, Wake Forest University, Winston Salem, USA

  K.C Balaji

K.C. Balaji, MD

Chief of Urology, W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina

Professor of Urology and Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina

Department of Urology, Cancer Biology, Institute of Regenerative Medicine

Wake Forest University School of Medicine, W.G. (Bill) Hefner VA Medical Center

Winston Salem, NC, USA

Mailing Address:

Department of Urology, Medical Center Blvd,

Winston Salem, NC 27157

T: 336 716 5690

F: 336 716 5711

Email: kbalaji@wakehealth.edu

Policies and ethics